Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· Aging JournalAudio: American English

Proposed control-theory framework for gerotherapeutic drug discovery

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →

At a glance

Automatic summary · not editorially reviewed

The description presents a proposed control-theory framework that defines biological age as the minimum safe control cost of functional restoration and claims control-value reduction predicts translational success better than hallmark annotation or biomarker reversal alone. [1]

  1. The description says existing aging theories describe what changes with age but do not prescribe how to intervene, and that the authors propose a prescriptive control-theoretic framework. [1]

  2. The description says drugs are modeled as vector fields and that their non-commutativity, quantified by Lie brackets, predicts that intervention order determines outcome. [1]

  3. The description states the central claim that control-value reduction predicts translational success better than hallmark annotation or biomarker reversal alone, and frames the framework as providing the missing interventional layer if validated. [1]

Proposed prescriptive framework versus descriptive aging theories

According to the description, existing aging theories describe what changes with age but do not prescribe how to intervene. The authors propose a control-theoretic framework they call prescriptive: it is meant to specify which intervention, at which dose and sequence, under which safety constraints, restores a measured biological state to a functional region. Aging is defined as progressive loss of safe controllability, and biological age as the minimum safe control cost of functional restoration. The description attributes the paper to Alex Zhavoronkov and Bud Mishra and says it was published in Aging on September 16, 2026, in Volume 18. [1]

Drug order, five-dimensional model and twenty predictions

The description says drugs are modeled as vector fields on biological state space, and that their non-commutativity, quantified by Lie brackets, predicts that intervention order determines outcome. It reports a five-dimensional model of differential equations with analytic derivation of the Lie brackets, a control layer that accounts for modality, three translational case studies, an implementation architecture with power analysis, and empirical scoring of aging interventions across five biological epochs. Twenty falsifiable predictions are said to be enumerated. The framework is described as outputting ranked targets, optimal sequences, safety-constrained protocols and falsifiable predictions intended for drug discovery, rather than mechanistic ontologies or correlative biomarkers. [1]

Central claim framed as conditional on validation

The description states the central claim as follows: control-value reduction predicts translational success better than hallmark annotation or biomarker reversal alone. It presents this as a claim to be tested, adding that if validated, the framework would provide the missing interventional layer connecting aging biology to rational gerotherapeutic discovery. The description does not report that the framework has been validated, nor does it report human lifespan or clinical outcomes. [1]

Context & limits

This is based only on the video description; the video and transcript were not reviewed. The description reports a proposed framework and its stated claims, not validated results, and gives no human lifespan or clinical outcome data.

Based on the creator’s description; the full video and transcript were not analyzed.

[1] Control Theory of Aging and Longevity: Optimizing Gerotherapeutic Drug Discovery | Aging
Quoted passages in the original language
do not prescribe how to intervene
intervention order determines outcome
If validated, this provides the missing interventional

About this video

Creator description · original textText language: English

Aging published this #Trending research paper on September 16, 2026, in Volume 18, titled “Control theory of aging and longevity for gerotherapeutic drug discovery: state space, vector fields, modalities, safety, and the minimum safe cost of functional restoration" by Aging Editorial Board member Alex Zhavoronkov and Bud Mishra, who are affiliated with Insilico Medicine Hong Kong Ltd., Hong Kong SAR, China; Insilico Medicine Shanghai Ltd., Pudong 201203, Shanghai, China; Insilico Medicine AI Ltd., Masdar, Abu Dhabi, UAE; Insilico Medicine US Inc., Cambridge, MA; Buck Institute for Research on Aging, Novato, CA; Courant Institute School of Mathematics, Computer and Data Sciences, New York University, New York, NY. @InsilicoMedicine #Aging #Longevity #DrugDiscovery #Gerotherapeutics #Research #OpenAccess #PeerReviewed #Journal #Publishing #MedEd DOI - https://doi.org/10.18632/aging.206422 Corresponding author - Alex Zhavoronkov - alex@insilicomedicine.com Abstract Existing aging theories describe what changes with age but do not prescribe how to intervene. We propose a control-theoretic framework that is not merely descriptive but prescriptive: it specifies which intervention, at which dose and sequence, under which safety constraints, will restore a measured biological state to a functional region. Aging is defined as progressive loss of safe controllability; biological age is the minimum safe control cost of functional restoration. Drugs are modeled as vector fields on biological state space whose non-commutativity, quantified by Lie brackets, predicts that intervention order determines outcome. The core differentiation from prior theories is operational: the framework outputs ranked targets, optimal sequences, safety-constrained protocols, and falsifiable predictions directly usable in drug discovery, rather than mechanistic ontologies or correlative biomarkers. We present a five-dimensional ODE model with analytic Lie-bracket derivation, a modality-aware control layer, three translational case studies, an implementation architecture with power analysis, and empirical scoring of aging interventions across five biological epochs. Twenty falsifiable predictions are enumerated. The central claim is that control-value reduction predicts translational success better than Hallmark annotation or biomarker reversal alone. If validated, this provides the missing interventional layer connecting aging biology to rational gerotherapeutic discovery. Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206422 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, control theory, biological age, drug discovery, gerotherapeutics To learn more about the journal, please visit https://www.Aging-US.com​​ and connect with us on social media at: Bluesky - https://bsky.app/profile/aging-us.bsky.social ResearchGate - https://www.researchgate.net/journal/Aging-1945-4589 X - https://twitter.com/AgingJrnl Facebook - https://www.facebook.com/AgingUS/ Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Reddit - https://www.reddit.com/user/AgingUS/ Pinterest - https://www.pinterest.com/AgingUS/ YouTube - https://www.youtube.com/@Aging-US Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

Aging Journal · 2 min · Source published: 2026-10-14

Added to Harbor: 10/23/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…